signal regulatory protein deltaGenealiases: PTPNS1L2 · dJ576H24.4
Q-omics provides the consensus-scored SIRPD profile across patient tissues and cancer cell-line models. SIRPD expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SIRPD is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, SIRPD RNA expression shows 13,386 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight CESC, KIRC, and DLBC as cancer lineages where SIRPD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIRPD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIRPD survival associations across molecular data types. SIRPD RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIRPD RNA expression–survival associations across cancer types. High SIRPD expression shows unfavorable associations in KICH, UVM, LGG and ACC, but favorable associations in CESC and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SIRPD RNA expression.
This table summarizes SIRPD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SIRPD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIRPD shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, STAD and HNSC. The KIRC box plot shows higher SIRPD RNA expression in tumor versus normal tissue (log2 FC = +0.329, t-test p < 0.001).
This table shows molecular features associated with SIRPD in patient tissues and cancer cell lines. In patient samples, SIRPD shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, SIRPD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
